Commentary
Video
Dr Shah on Remaining Unmet Needs in RCC After Frontline IO Combinations
Author(s):
Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.
Neil J. Shah, MBBS, assistant attending physician, genitourinary oncologist, Memorial Sloan Kettering Cancer Center, discusses unmet needs for patients with renal cell carcinoma (RCC) receiving immune-oncology (IO)–based combinations in the frontline setting.
Most patients with advanced RCC will receive an IO/IO or IO/TKI combination in the frontline setting, but unmet needs remain for these patients. Shah and coauthors presented a real-world study during 2024 Kidney Cancer Research Summit, which demonstrated that patients with RCC who received various IO/IO and IO/TKI combinations all experienced similar outcomes, and there is limited overall survival in the post-IO/IO and -IO/TKI setting, underscoring the need for the development of more novel therapies in the space.
